ACADIA Pharmaceuticals Inc. (ACAD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 442 | 484 | 517 | 726 | 958 | 1,072 | 1,139 | 1,272 |
| Operating profit | $m | 105 | 86 | ||||||
| Net profit | $m | -282 | -168 | -216 | -61 | 226 | 391 | 380 | 104 |
| EPS reported | $ | 2.29 | 2.22 | ||||||
| Operating cashflow per share | $ | 0.65 | 1.13 | ||||||
| Capex per share | $ | 0.03 | 0.12 | ||||||
| FCF per share | $ | 0.62 | 1.02 | ||||||
| Free cash flow | $m | 105 | 174 | ||||||
| Net debt | $m | -808 | -942 | ||||||
| Book value equity | $m | 1,227 | 1,307 | ||||||
| Book value per share | $ | 7.16 | 7.56 | ||||||
| Number of shares | m | 171.36 | 172.85 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 11.66 | 9.25 | ||||||
| P/B LTM | x | 3.69 | 3.46 | ||||||
| P/S LTM | x | 4.22 | 3.97 | ||||||
| P/FCF LTM | x | 43.02 | 25.94 | ||||||
| EV/EBITDA LTM | x | 29.19 | 37.87 | ||||||
| EV/Sales LTM | x | 4.10 | 3.94 | ||||||
| Earnings Yield LTM | % | +8.58% | +10.81% | ||||||
| FCF Yield | % | +2.32% | +3.86% | ||||||
| Quality | |||||||||
| ROE | % | +31.86% | +32.39% | ||||||
| ROIC | % | +8.07% | +6.19% | ||||||
| Operating margin | % | +9.78% | +7.59% | ||||||
| Gross margin | % | +91.69% | +91.13% | ||||||
| FCF/Sales | % | +9.81% | +15.32% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +68.38% | +63.24% | ||||||
| Sales Growth YoY | % | +11.87% | +18.88% | ||||||
| Net Income Growth YoY | % | +72.66% | +68.02% | ||||||
| FCF Growth | % | -33.11% | +10.94% | ||||||
| Operating Profit Growth | % | -54.59% | -62.58% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 2.01 | 2.36 | ||||||
| Net Debt/EBITDA | x | -0.83 | -2.68 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.26% | 0.00% | ||||||
| Net debt/Equity | x | -0.66 | -0.72 | ||||||
| Gross debt/equity | x | 0.04 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ACADIA Pharmaceuticals Inc. (ACAD)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free